To investigate the efficacy of cyclophosphamide combined with prednisone in membranous nephropathy (MN) patients with different cytochrome P450 (CYP) 2B6 gene polymorphisms and explore the factors influencing the efficacy.
We performed a prospective and interventional study including 153 outpatients diagnosed with membranous nephropathy from April 2020 to June 2020 in the Bayannur Hospital. Based on the results of CYP2B6 gene polymorphisms, patients were divided into CYP2B6*4 group (785A>G) with 93 cases and CYP2B6*5 group (1459C>T) with 60 cases, and all patients were treated with cyclophosphamide and prednisone. The efficacy of the two groups was compared, and the serum levels of antibody against thrombospondin type-1 domain-containing 7A (THSD7A-Ab), 8-hydroxy-2’-deoxyguanosine (8-OHdG) and antibody against the M-type phospholipase A2 receptor (PLA2R-Ab) determined by the enzyme-linked immunosorbent method were analyzed in the two groups before and after treatment.
After the treatment with cyclophosphamide and prednisone, serum levels of THSD7A-Ab, 8-OHdG, and PLA2R-Ab were higher in the CYP2B6*4 group than those in the CYP2B6*5 group (All three P<0.001). The univariate Logistic regression analysis showed that CYP2B6*4 (OR = 1.727, 95% CI: 1.028–2.654. P=0.012), CYP2B6*5 (OR = 1.802, 95% CI: 1.179–2.752. P=0.031), THSD7A-Ab (OR = 1.832, 95% CI: 0.871–2.348. P=0.023), 8-OHdG (OR = 1.661, 95% CI: 1.123–2.231. P=0.009), PLA2R-Ab (OR = 1.649, 95% CI: 1.083–2.761. P=0.017) were independent influencing factors on the efficacy of MN. The multivariate Logistic regression analysis showed that CYP2B6*4 (OR = 2.009, 95% CI: 1.327–2.703. P<0.001), CYP2B6*5 (OR = 3.009, 95% CI: 1.467–5.231. P=0.005), THSD7A-Ab (OR = 1.396, 95% CI: 1.002–1.897. P=0.019), 8-OHdG (OR = 0.704, 95% CI: 0.591–0.742. P<0.001), PLA2R-Ab (OR = 2.761, 95% CI: 1.231–3.918. P=0.017) were independent factors influencing the efficacy of cyclophosphamide and prednisone on MN.